Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia

NCT04541186 is registered in ClinicalTrials.gov with 89bio, Inc. as lead sponsor.

NCT NCT04541186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04541186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia
Lead sponsor
89bio, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 1, 2020
Completion date
May 31, 2022
Enrollment
86 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

severe hypertriglyceridemia